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AbstrAct
HER2-targeted therapy has been shown to have limited efficacy in ovarian cancer 
despite frequent overexpression of this receptor. Photochemical internalization (PCI) 
is a modality for cytosolic drug delivery, currently undergoing clinical evaluation. In 
the present project we studied the application of PCI in combination with the HER2-
targeted recombinant fusion toxin, MH3-B1/rGel, for the treatment of ovarian cancer. 
The SKOV-3 cell line, resistant to trastuzumab- and MH3-B1/rGel- monotherapy, was 
shown to respond strongly to PCI of MH3-B1/rGel to a similar extent as observed for 
the treatment-sensitive SK-BR-3 breast cancer cells. Extensive hydrolytic degradation 
of MH3-B1/rGel in acidic endocytic vesicles was indicated as the mechanism of 
MH3-B1/rGel resistance in SKOV-3 cells. This was shown by the positive Pearson’s 
correlation coefficient between Alexa488-labeled MH3-B1/rGel and Lysotracker 
in SKOV-3 cells in contrast to the negative Pearson’s correlation coefficient in SK-
BR-3 cells. The application of PCI to induce the release of MH3-B1/rGel was also 
demonstrated to be effective on SKOV-3 xenografts. Application of PCI with MH3-B1/
rGel was further found highly effective in the HER2 expressing HOC-7 and NuTu-19 
ovarian cancer cell lines. The presented results warrant future development of PCI in 
combination with MH3-B1/rGel as a novel therapeutic approach in preclinical models 
of ovarian cancer. 
IntroductIon
Ovarian cancer is the most lethal of gynecologic 
cancers. It is often diagnosed at a late stage and the 
sensitivity to available anticancer therapeutics is highly 
limited. New treatment approaches are therefore warranted 
for the management of this disease. HER2 overexpression 
is most commonly associated with breast cancer where 
HER2 overexpression is found in 20-30 % of the cases [1]. 
Several HER2-targeted therapeutics have been approved 
for clinical use in the treatment of breast cancer. However, 
despite the success of HER2-targeted drugs in treating 
breast cancer, de novo as well as acquired resistance are 
major limitations in clinical practice [2], leaving patients 
with very limited treatment options. In case of ovarian 
cancer with known HER2 expression, several HER2-
targeted drugs have been evaluated in clinical trials [3, 
4, 5]. However, no HER2-targeted drug has so far been 
approved for clinical use, despite HER2 overexpression 
being reported in up to 35 % of all ovarian cancers [6, 
7]. New HER2-targeted modalities with increased toxicity 
and less potential for development of resistance should 
therefore be an interesting approach for future treatment 
of ovarian cancer. 
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Increased toxicity of HER2-targeted drugs may be 
achieved through the utilization of single-chain HER2 
antibody-based immunotoxins. Such constructs have 
been proven highly HER2 specific in vitro and induce 
considerable tumor growth delay in several animal models 
[8, 9, 10, 11]. The toxin component in such drugs acts by 
inhibition of protein synthesis and provides increased 
cytotoxic potential compared to clinically available 
HER2-targeted monoclonal antibodies (mAbs) and 
tyrosine kinase inhibitors (TKIs). Off-target cytotoxicity, 
which generally has been considered a major limitation for 
clinical use of immunotoxins, may be reduced by utilizing 
a type 1 ribosome-inactivating protein (RIP) [12]. In 
contrast to highly potent toxins such as ricin, Pseudomonas 
exotoxin (PE) and diphtheria toxin, type 1 RIPs lack a 
translocation domain which transports the toxin from 
endosomes into the cytosol [13]. Thus, a technology which 
allows improved endo/lysosomal release of these agents 
has the potential to increase specific cytotoxicity provided 
by type 1 RIP-based immunotoxins [14]. Photochemical 
internalization (PCI) is a technology which causes 
cytosolic release of drugs entrapped in endocytic vesicles 
[15, 16]. PCI is based on an amphiphilic photosensitizer 
(PS) which accumulates in the membranes of endosomes 
and lysosomes. Light exposure with appropriate 
wavelengths, excites the PS and initiates the production of 
reactive oxygen species (ROS) which in turn destroys the 
endo/lysosomal membrane [17]. PCI of several drugs has 
been proven as an effective treatment modality for cancer 
in vivo [18, 19, 20, 21] and ongoing clinical studies on PCI 
are showing highly promising results (www.clinicaltrials.
gov; NCT01606566, NCT01872923, NCT01900158).
In the present study we evaluated PCI of the 
HER2-targeted single chain antibody-based recombinant 
immunotoxin MH3-B1/rGel in three ovarian cancer cell 
lines, generally resistant to HER2-targeted therapy, and 
also on ovarian cancer xenografts in athymic mice. These 
results indicate PCI of HER2-targeted toxins to be a 
promising treatment modality for HER2 overexpressing 
ovarian cancer and warrants future evaluation in 
preclinical models. 
results 
Her2 expression among the cell lines
The HER2 expression level in the 4 selected human 
cancer cell lines was found to vary in agreement with 
other reports. Both SK-BR-3 and SKOV-3 were found to 
be HER2-high expressing and the HER2 level in SK-BR-3 
was indicated higher than observed in the SKOV-3 cells 
[10, 28] (Fig. 1A). An intermediate HER2 expression was 
found in the HOC-7 cell line [29] (Fig. 1A) while MDA-
MB-468 was indicated as HER2-low [30, 10] (Fig. 1A). 
A weak HER2 band was also detected on overexposed 
western blots of Nu-Tu-19 cells (rat orgin) (Fig. 1A). 
However, the apparent weak HER2 expression in Nu-
Tu-19 cells may be due to poor recognition of HER2 rat 
antigen by the antibody (antibody against human HER2) 
and comparison of HER2 level between Nu-Tu-19 and the 
human cell lines is therefore not possible. 
sensitivity of sK-br-3 and sKoV-3 cells to 
Her2-targeted therapeutics
In this study, the responsiveness to PCI of MH3-B1/
rGel was primarily evaluated in 2 HER2 overexpressing 
cell lines; the human breast cancer cell line SK-BR-3 and 
the human ovarian cancer cell line SKOV-3 (Fig. 1A). 
Subjecting the 2 cell lines to a 72 hrs incubation of the 
HER2-targeted immunotoxin MH3-B1/rGel revealed a 
low TI50 of ~2.4 in the SKOV-3 cell line, compared to 
the TI50 of ~136 in SK-BR-3 cells (Fig. 1B and 1C). The 
lack of response to MH3-B1/rGel in SKOV-3 cells was 
also reflected in the response to the scFv targeting moiety 
MH3-B1 which reduced the viability by ~20 % in SKOV-
3 cells compared to ~60 % in SK-BR-3 cells following 
a 72 hrs incubation at a 10 µM concentration (Fig. 1D). 
The SKOV-3 cells were in addition found resistant to the 
HER2-targeted mAb trastuzumab (Fig. 1E), in agreement 
with previous reports [29, 31] while the SK-BR-3 cells 
responded well with an LD50 of ~100nM. The present 
results therefore indicate that SKOV-3 cells are generally 
resistant to HER2-targeted antibody-based therapy. 
uptake and cellular localization of Alexa488-
MH3-b1/rGel in sK-br-3 and sKoV-3 cells
PCI is a method for cytosolic release of drugs 
entrapped in endosomes and lysosomes. PCI in vitro 
is usually performed by a 1-18 hrs incubation of the 
macromolecule of interest prior to light exposure 
[32, 17]. This relatively short incubation time of the 
macromolecule is utilized to avoid strong influence of 
lysosomal degradation on the PCI outcome. In the present 
in vitro protocol, a 4 hrs pulse of 2 nM MH3-B1/rGel was 
used prior to the light exposure. Since the intracellular 
trafficking of MH3-B1/rGel in the post-treatment period 
is expected to influence on the therapeutic effect, a 
cytotoxicity evaluation was performed 72 hrs after the 
4 hrs pulse of MH3-B1/rGel to verify that SKOV-3 cells 
were resistant to MH3-B1/rGel also after a 4 hrs treatment 
(Fig. 2A and 2B). The TI’s after 4 hrs treatment were 
found to be higher in both cell lines compared to that after 
72 hrs treatment. However, the SKOV-3 cells were found 
to be relatively less sensitive to the treatment as e.g. 2 nM 
MH3-B1/rGel reduced cell viability by ~35 % in SK-BR-3 
cells (Fig. 2B), but did not induce detectable cytotoxicity 
in the SKOV-3 cell line (Fig. 2A). Calculating the TI at 
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Figure 1: cellular Her2 expression and cytotoxicity of Her2-targeted compounds. (A). Western blot showing basal HER2 
expression in SK-BR-3, SKOV-3, MDA-MB-468, HOC-7 and Nu-Tu-19 cells, representative blot of two experiments. Relative cell viability 
(MTT) of SKOV-3 and SK-BR-3 cells following 72 hrs incubation with MH3-B1/rGel and rGel (b and c), MH3-B1 (d) and trastuzumab 
(e), representative sigmoidal curves of three experiments (fit model: a/(1+exp(-(x-x0)/b))), error bars = SD. 
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Figure 2: cytotoxicity, uptake and cellular localization of MH3-b1/rGel after 4 hrs incubation. Relative cell viability 
(MTT) of SK-BR-3 (A) and SKOV-3 (b) following 4 hrs incubation with MH3-B1/rGel, rGel and MH3-B1, representative sigmoidal 
curves of three experiments, (fit model: a/(1+exp(-(x-x0)/b))), error bars = SD. (c): Cellular uptake of 2 nM Alexa488-MH3-B1/rGel 
following 4 hrs incubation in SK-BR-3 and SKOV-3 cells, representative flow cytometry charts of three experiments. (d): Total cellular 
Alexa488-MH3-B1/rGel fluorescence, average of three experiments, error bars = SE. (e): SK-BR-3 and SKOV-3 cells following 4 hrs 
incubation of 2 nM Alexa-488-MH3-B1/rGel. Alexa488-MH3-B1/rGel (green), LTR (blue) and colocalization of the two (white). The 
confocal micrographs are representative of three independent experiments. The colocalization of Alexa488-MH3-B1/rGel with LTR 
was calculated by the Manders’ thresholded coefficient from the total cellular accumulation measured (F) and the Pearson’s correlation 
coefficient was used to calculate the correlation between Alexa488-MH3-B1/rGel and LTR based on fluorescence intensities/pixel (G), F 
and G shows average of three experiments, error bars = SE.
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IC35 of MH3-B1/rGel vs. rGel (TI35) revealed an ~11-
fold higher TI35 in SK-BR-3 cells compared to SKOV-3 
cells after 4 hrs treatment with MH3-B1/rGel. SKOV-3 
cells were therefore found resistant to MH3-B1/rGel also 
when administrated for 4 hrs compared to SK-BR-3 cells. 
Four hrs incubation of MH3-B1 (without rGel) did not 
induce any significant cytotoxicity in any of the cell lines, 
indicating MH3-B1/rGel-mediated toxicity to be generated 
through ribosomal inhibition (Fig. 2A and 2B). 
MH3-B1/rGel primarily exerts its intracellular 
action by inducing inhibition of protein synthesis. The 
mechanism of MH3-B1/rGel resistance in the SKOV-3 
cell line could be due to differences in overall uptake and/
or intracellular MH3-B1/rGel localization and trafficking 
compared to SK-BR-3 cells. Subjecting SK-BR-3 and 
SKOV-3 cells to a 4 hrs incubation of 2 nM Alexa488-
labeled MH3-B1/rGel revealed a ~2-fold higher Alexa488-
MH3-B1/rGel uptake in SK-BR-3 cells compared to 
SKOV-3 cells (Fig. 2C and 2D). However, this 2-fold 
difference could only partly explain the ~11-fold higher 
TI35 in SK-BR-3 cells following a 4 hrs MH3-B1/rGel 
incubation (Fig. 2A and 2B). 
The MH3-B1/rGel construct must eventually 
translocate from endosomes and/or lysosomes into 
the cytosol to exert its action on the ribosomes and 
avoid lysosomal degradation [12]. Thus, differences in 
distribution of the targeting toxin in endocytic vesicles 
between SKOV-3 and SK-BR-3 cells could explain the 
difference in MH3-B1/rGel sensitivity. Intracellular 
localization of Alexa488-labeled MH3-B1/rGel was 
detected by confocal microscopy which confirmed both 
binding of the immunotoxin to the plasma membrane 
and cellular internalization to endocytic compartments 
in both cell lines (Fig. 2E). The association of Alexa488-
MH3-B1/rGel to the plasma membrane appeared much 
stronger in the SK-BR-3 cells than in the SKOV-3 cells. 
However, this visual appearance may at least partly be 
due to the more rounded up morphology of the SK-BR-3 
Figure 3: PCI efficacy of MH3-B1/rGel in SK-BR-3 and SKOV-3 cells. Relative cell viability (MTT) of SK-BR-3 (A), SKOV-3 
(b) and MDA-MB-468 (c) cells after PCI of 2 nM MH3-B1/rGel (incubated for 4 hrs), representative curves from three experiments, error 
bars = SD. (d): rGel-corrected PCI efficacy, average of three experiments, in SK-BR-3, SKOV-3 and MDA-MB-468 cells. 
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cells. Diffuse fluorescence was, in addition, observed in 
the cytoplasm of SKOV-3 cells. The thin morphology 
of SKOV-3 cells (~1.5 µm), together with the axial 
resolution of the microscope (0.56 µm) and differences 
in the optimal plane of microscopy between cells in the 
same micrograph was, however, found as the reason for 
this diffuse fluorescence which was concluded as noise 
from the plasma membrane. A significantly higher fraction 
(15.2 % vs. 9.6 %) of Alexa488-MH3-B1/rGel was found 
to colocalize with LTR in SKOV-3 cells than in SK-BR-3 
cells (p = 0.0125) (Fig. 2F). The distribution of Alexa488-
MH3-B1/rGel correlated also better with the distribution 
of LTR as revealed by the Pearson’s correlation coefficient 
of 0.17 (±0.04) in SKOV-3 cells as compared to -0.059 
(±0.02) in the SK-BR-3 cells (p < 0.001) (Fig. 2G). A 
higher distribution of MH3-B1/rGel in acidic endocytic 
vesicles in SKOV-3 cells indicates a higher hydrolytic 
degradation of the immunotoxin in the vesicles of these 
cells compared to SK-BR-3 cells. This hydrolysis may 
take place in all acidic endocytic vesicles including both 
endosomes and lysosomes [33, 34]. Attempts have been 
made to remove plasma membrane associated fusion toxin 
in order to quantitatively measure intracellular fusion 
toxin. Such a method would make it possible to compare 
the impact of e.g. a lysosomotropic agent on MH3-B1/
rGel degradation in the two cell lines. However, the high 
plasma membrane association of MH3-B1/rGel in these 
two cell lines makes this a difficult task since only small 
contamination from the plasma membrane is likely to 
influence strongly on this suggested experiment. Thus, the 
increased distribution of Alexa488-MH3-B1/rGel in acidic 
vesicles in the SKOV-3 cell line together with the higher 
overall uptake in the SK-BR-3 cells may explain the lower 
sensitivity to MH3-B1/rGel in the SKOV-3 cells compared 
to SK-BR-3 cells. 
PcI of MH3-b1/rGel in sK-br-3 and sKoV-3 
cells
Since high hydrolytic degradation was indicated as 
a potential mechanistic cause of the low MH3-B1/rGel 
sensitivity in the SKOV-3 cells, we hypothesized that PCI 
may be useful in addressing this mechanism of resistance. 
Studies combining PCI and MH3-B1/rGel demonstrated 
highly effective cytotoxicity against SKOV-3 cells and 
appeared to reduce the cell viability to the same extent 
as observed for the SK-BR-3 cells (Fig. 3A and 3B). PCI 
of MH3-B1/rGel was also indicated as HER2 selective 
when compared to PCI of non-targeted rGel (Fig. 3A and 
3B) and also when comparing the PCI data for SK-BR-3 
and SKOV-3 cells with those obtained with the HER2 low 
expressing cell line MDA-MB-468 (Fig. 3A-3C). The 
efficacy of PCI of MH3-B1/rGel has recently been shown 
to correlate well with HER2 expression [23]. PCI efficacy 
may be established by comparing the light dose needed 
to obtain LD50 with PCI with that of the photochemical 
treatment (PS and light) and correct the calculation for 
cellular differences in sensitivity to the non-targeted toxin 
(as described in Materials and Methods, [23]). The PCI 
efficacy corrected for rGel-sensitivity in the two cell lines 
revealed similar efficacy of PCI of MH3-B1/rGel in the 
resistant SKOV-3 cells as in the SK-BR-3 cells (p > 0.05) 
(Fig. 3D). The rGel-corrected PCI efficacy in MDA-
MB-468 cells was, however, found to be 6.8- and 6.3-fold 
reduced compared to that in SK-BR-3 and SKOV-3 cells 
respectively (Fig. 3D). 
PcI of MH3-b1/rGel in Hoc-7 and nutu-19 cells
Ovarian cancer is generally known to have low 
sensitivity to HER2-targeted therapeutics despite strong 
HER2 expression [3, 5]. The high PCI-induced efficacy 
of MH3-B1/rGel in SKOV-3 cells was therefore also 
tested in the ovarian cancer cell lines HOC-7 and NuTu-
19. HOC-7 cells were found resistant to trastuzumab and 
MH3-B1/rGel to a comparable level as detected in SKOV-
3 cells (Fig. 4A and 4B, Fig. 1B and 1E). Accordingly, 
NuTu-19 cells have previously been reported to not 
respond to trastuzumab [35] and were also found resistant 
to MH3-B1/rGel (Fig. 4C). PCI was shown to increase the 
effect of MH3-B1/rGel significantly in HOC-7 and Nu-
Tu-19 cells (Fig. 4D and 4E), indicating that MH3-B1/
rGel is accumulating specifically in both cell lines 
although the therapeutic specificity is more strongly seen 
after activation by PCI. These results are in accordance 
with those seen in the SKOV-3 cells (Fig. 3B). HER2 
expression in HOC-7 cells was, however, much lower than 
observed for SKOV-3 cells (Fig. 1A). 
PcI of MH3-b1/rGel on sKoV-3 xenografts in 
vivo
The high efficacy of PCI of MH3-B1/rGel in 
the MH3-B1/rGel resistant SKOV-3 cells was further 
evaluated on SKOV-3 subcutaneous xenografts in athymic 
mice. This is a relatively slow growing tumor model and 
the mean time to reach the endpoint of 800 mm3 from 
a treatment volume of ~100 mm3 was 43.4 days (Fig. 
6D). The photochemical treatment induced edema and 
accurate measurements of tumors were therefore difficult 
to obtain the first ~2 weeks after treatment. Early effects 
on tumor growth following the different treatments were 
assessed on day 16 since this was the first day without any 
detectable edema in any of the animals. Comparing the 
size of all tumors at day 16 revealed significantly smaller 
tumors in the PCI group compared to the control groups 
receiving either MH3-B1/rGel, photochemical treatment 
or no treatment (Fig. 5A and 5C). No significant difference 
was found between the no treatment group and the groups 
receiving MH3-B1/rGel or photochemical treatment as 
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Figure 4: PcI of MH3-b1/rGel in Hoc-7 and nutu-19 cells. Relative cell viability (MTT) of HOC-7 cells following 72 
hrs incubation with trastuzumab (A) and MH3-B1/rGel and rGel (b). Relative cell viability (MTT) of NuTu-19 cells following 72 hrs 
incubation with MH3-B1/rGel and rGel (c). Representative sigmoidal curves of three experiments (fit model: a/(1+exp(-(x-x0)/b)), error 
bars = SD. (d) and (e) shows relative cell viability (MTT) of HOC-7 and NuTu-19 cells after PCI of 2nM MH3-B1/rGel (incubated for 4 
hrs), representative curves of three experiments, error bars = SD.
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Figure 5: tumor size after PcI of MH3-b1/rGel in sKoV-3 xenografts. The bars show the measured tumor size at day 16 for 
each animal in the four treatment groups (A) and the percent change in tumor size at day 16 calculated from the measured tumor size at 
treatment day (day 0) for each animal in the four treatment groups (b). Calculated p-values representing statistical differences in tumor size 
between the treatment groups at day 16 post treatment (c).
Oncotarget12444www.impactjournals.com/oncotarget
monotherapies. Neither was there any difference in tumor 
size between the group receiving MH3-B1/rGel and the 
photochemical treatment group at day 16 (Fig. 5A and 
5C).
The percent change in tumor size at day 16 
compared to the tumor size measured at day 0 for each 
animal, revealed a stronger inhibition of tumor growth in 
the PCI group than in the control groups. All the animals 
in the MH3-B1/rGel monotherapy and no treatment group 
showed an increase in tumor volume at day 16 compared 
to day 0 (Fig. 5B). However, the tumors subjected to the 
photochemical treatment (PS and light) showed an overall 
lower growth and even some reduction in tumor volume. 
The volume of the tumors in the PCI group was even 
smaller than those only subjected to the photochemical 
treatment (PS and light) and a higher number of tumors 
showed a reduced tumor volume.
Although statistically not significant, a treatment 
response of SKOV-3 tumors following PCI of MH3-B1/
rGel was also indicated in Kaplan-Meier plots between 
day 38 and 50 post light exposure (Fig. 6A). At day 50, 
44 % of the animals that received PCI of MH3-B1/rGel 
had tumors with a size < 800 mm3 compared to 20 % in 
the photochemical treatment group, whereas all the tumors 
in the no treatment group and the group that received 
MH3-B1/rGel monotherapy had reached the end point 
of 800 mm3 (Fig. 6A). Measurements of tumor growth 
delay confirmed treatment response in the PCI group 
compared to the control groups also at day 20, 30 and 40 
post-treatment as illustrated in Fig. 6C. The mean time 
to reach a tumor volume of 800 mm3 is presented in Fig. 
6D and growth curves is presented in S1. No correlation 
was found between the actual tumor size at the day of 
treatment and treatment response.
The effect of the applied PCI treatment was smaller 
than expected from the encouraging in vitro data presented 
here in addition to previous in vivo reports on PCI of other 
targeting toxins [20, 21]. The 48 hrs interval between 
MH3-B1/rGel administration and light exposure used 
in this study was based on MH3-B1/rGel accumulation 
Figure 6: treatment response following PcI of MH3-b1/rGel in sKoV-3 xenografts. Kaplan Meyer plot illustrating response 
from day 34-50 in the four treatment groups (A). Tumor volume end point = 800 mm3. Western blot of HER2 in three SKOV-3 tumors 
(b). Percent of animals bearing tumors < 100 mm3 at day 20, < 250 mm3 at day 30 and < 800 mm3 at day 40 post light exposure in the four 
treatment groups (c). Average time to reach the endpoint of 800 mm3 tumor volume in the four treatment groups (d).
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studies in BT474 M1 tumors [9] and this interval was 
decreased to 24 hrs to study if this would increase the 
treatment response. No increase in efficacy was, however, 
detected by reducing the MH3-B1/rGel-to-light interval to 
24 hrs (data not shown). Western blots of HER2 in three 
SKOV-3 tumors verified high expression of HER2 in these 
xenografts (Fig. 6B). 
tumor accumulation of MH3-b1/rGel in sKoV-3 
xenografts
The amount of MH3-B1/rGel localized to the tumor 
at the time of light exposure (48 hrs post injection) was 
assessed by western blotting of tumor lysates. These 
western analysis failed, however, to demonstrate the 
presence of the fusion construct in the tumors (results 
Figure 7: Adverse effects following PcI of MH3-b1/rGel in sKoV-3 xenografts. H&E staining of kidney and liver tissue in 
untreated and PCI of MH3-B1/rGel treated animals 24 hrs post light exposure (A). Bar: 50 μm. Serum levels of creatinine, AST and ALT 
in untreated and PCI of MH3-B1/rGel treated animals 24 hrs post light exposure (b).
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not shown). A standard of MH3-B1/rGel indicated 0.5 ng 
MH3-B1/rGel as the detection limit for MH3-B1/rGel on 
a western blot which would correspond to 208 ng (3.78 
x10-12 mol) MH3-B1/rGel/g tumor tissue in a 0.2 g tumor. 
The amount of MH3-B1/rGel localized to the tumors at 
the time of light exposure with the present protocol was 
therefore less than 3.78 x 10-12 moles/g tumor tissue. 
Adverse effects of the treatment
Damage to the liver and kidneys of mice was 
evaluated 24 hrs after the PCI treatment. No adverse 
effects on the kidneys were noted by histopathology 
and also by measuring the serum levels of creatinine, 
an indicator of renal function (Fig. 7A and 7B). 
Hepatocytes, however, showed their central nuclei 
surrounded by many vacuoles in the cytoplasm (Fig. 7A), 
a typical morphological alteration indicating reversible 
degeneration. This is consistent with the results which 
demonstrated a significant increase in serum levels of 
AST and ALT (Fig. 7B) in the PCI-treated animals. 
Such reversible hepatic degeneration indicates that the 
PCI treatment may induce a slight liver toxicity, but 
with no reduction in the daily activities as well as body 
weight of the treated mice. In the skin, erythema for up 
to 2 weeks was detected at the illuminated area, while 
light alone (without PS) as a control did not cause such 
effect. In addition, a small wound in the treated area was 
observed in 3 out of 10 mice, but leaving no scarring. 
Thus, generally, PCI of MH3-B1/rGel was considered as 
a tolerable treatment. 
dIscussIon
In the present study, we have utilized the 
intracellular drug delivery technology PCI to potentiate 
the cytotoxicity of the HER2-targeted recombinant 
immunotoxin, MH3-B1/rGel in HER2 overexpressing 
ovarian cancer cell lines. Ovarian cancer is the most 
lethal of all gynecological cancers with a 5 year survival 
of only 44.2% [36]. Up to 35% of ovarian cancers have 
been reported as HER2-positive [37, 6, 7]. HER2-targeted 
antibodies and molecular inhibitors have, however, failed 
to demonstrate significant clinical benefit as monotherapy 
[38] and the prognostic value of HER2 expression in 
ovarian cancer is controversial [38]. The aim of this study 
was to utilize HER2 as the delivery portal for MH3-B1/
rGel to endocytic vesicles in the ovarian cancer cell line 
SKOV-3. PCI-induced cytosolic translocation of MH3-B1/
rGel should further facilitate ribosomal binding, inhibition 
of protein synthesis and induction of cell death. The 
HER2-positive breast cancer cell line SK-BR-3, recently 
reported as highly sensitive to PCI of MH3-B1/rGel [23] 
was used as a positive control throughout the study.
Both SKOV-3 and SK-BR-3 cells were found to be 
HER2-positive, although HER2 was more pronounced 
in SK-BR-3 cells in agreement with a previous report 
[39]. The increased level of HER2 found in SK-BR-3 
cells could, however, not explain the ~60-fold higher TI 
(72 hrs incubation) of MH3-B1/rGel compared to the 
SKOV-3 cells or the significantly decreased sensitivity to 
MH3-B1 or trastuzumab in SKOV-3 cells. The mechanism 
of MH3-B1/rGel toxicity is dual because it (i): inhibits 
HER2 signaling and function through MH3-B1 and 
(ii): induces toxicity through the rGel payload which 
acts intracellulary by inactivating ribosomes leading 
to a generalized inhibition of protein synthesis. SKOV-
3 cells have also previously been reported resistant to 
trastuzumab [28, 31]. Trastuzumab resistance in SKOV-
3 cells is shown to depend on a constitutive activation 
of AKT, caused by lack of the tumor suppressor protein 
RAS homolog member I and also on low expression of 
PTEN which is recruited to the plasma membrane upon 
trastuzumab–HER2 association and inhibits AKT as one 
of the main mechanisms of trastuzumab induced G1 arrest 
[28, 40]. MH3-B1 binds to another domain of HER2 
than trastuzumab (results not published). The present 
results show, however, that SKOV-3 cells are resistant 
also to MH3-B1. AKT inhibition post MH3-B1 treatment 
was not assessed in the present study, and has not been 
reported before. However, the observed cross-resistance 
between trastuzumab and MH3-B1 may indicate a partial 
overlapping mechanism of resistance between these two 
HER2-targeted compounds. 
In our study, 72 hrs treatment of MH3-B1/rGel 
in SKOV-3 cells induced only minor toxicity by HER2 
inhibition as shown by the MH3-B1-induced reduction in 
viability at comparable concentrations. Four hrs incubation 
of MH3-B1 did not induce any reduction in viability in 
SKOV-3 or SK-BR-3 cells at doses < 10 µM (Fig. 2A and 
2B). The ~11-fold increased TI of MH3-B1/rGel in SK-
BR-3 cells compared to the SKOV-3 cell line after a 4 hrs 
incubation of the toxins therefore indicate that SKOV-3 
cells are resistant also to the gelonin-induced toxicity of 
MH3-B1/rGel.
PCI is a method for cytosolic release of therapeutics 
entrapped in endocytic vesicles [17]. Endocytic trapping 
and subsequent hydrolytic degradation of MH3-B1/rGel 
as an important mechanism of resistance in SKOV-3 
cells was shown by the efficacy of PCI in this cell line. 
The similar efficacy of PCI of MH3-B1/rGel (rGel-
corrected PCI efficacy) in SKOV-3 and SK-BR-3 cells 
found (Fig. 3D), despite the ~2-fold higher MH3-B1/rGel 
accumulation in SK-BR-3 cells (Fig. 2D), also suggests a 
higher distribution of MH3-B1/rGel to endocytic vesicles 
in SKOV-3 cells. The higher distribution of MH3-B1/rGel 
in acidic vesicles in SKOV-3 cells is also reflected in the 
higher Pearson’s correlation coefficient of MH3-B1/rGel 
and LTR found in this cell line (Fig. 2G). A more detailed 
mechanistic explanation on MH3-B1/rGel resistance 
should be addressed in future studies. These studies may 
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include siRNA targeting different cathepsins and also 
inhibitors of hydrolytic activity. 
PCI of MH3-B1/rGel on SKOV-3 xenografts in 
nude mice also revealed significantly smaller tumors 
in the PCI group compared to all control groups when 
measured 16 days after light exposure. This in vivo effect 
was smaller than expected based on the presented in 
vitro results and also on other reports on PCI of gelonin-
based immunotoxins [20, 21]. It has previously been 
shown that as little as 6.3 x 10-12 moles/g tumor tissue is 
sufficient for complete remission with an immunotoxin 
based on PE (anti-Tac(Fv)-PE38) [41]. We have tried, 
by western blotting, to evaluate the amount of MH3-B1/
rGel present in SKOV-3 tumors 48 hrs post i.v. injection 
of doses of 2 mg/kg (0.05 mg/mouse). We believe that 
this dose was likely below the limit of detection of our 
western analysis which was found to correspond to 3.78 
x10-12  moles/g tumor tissue. Compared to PE, rGel lacks 
a domain for cytosolic translocation [13]. If PCI can 
induce a 100% cytosolic release of MH3-B1/rGel, the 2 
mg/kg dose administered 48 hrs prior to light exposure 
is still significant less than what has previously been 
indicated as a curative dose of PE. However, we find it 
highly promising that the small amount of tumor-localized 
MH3-B1/rGel appears to demonstrate antitumor activity in 
combination with PCI. 
In the present study, only a single i.v. injection 
at a dose of 2 mg/kg was used. The increased efficacy 
provided by PCI has previously been shown to induce 
complete responses following only one injection of 
gelonin-based immunotoxins at comparable doses as 
here applied, however, the lack of severe adverse effects 
following 2 mg/kg of MH3-B1/rGel suggests that this dose 
may be increased to improve the PCI-induced efficacy. A 
significant effect on tumor growth delay has previously 
been reported after a fractionated dose (6 injections 
in 10 days) of 24 mg/kg MH3-B1/rGel [9]. This report 
therefore warrants a demonstration of higher single doses 
of MH3-B1/rGel, than currently available, in combination 
with PCI.
Altogether, the presented data suggest PCI of 
MH3-B1/rGel as a HER2-targeted treatment approach 
for HER2-positive cancers, including ovarian cancers 
resistant to HER2-targeted therapeutics. We have recently 
reported that PCI of MH3-B1/rGel exerts HER2-induced 
toxicity also in breast cancer with low HER2 expression 
[23]. PCI of MH3-B1/rGel may therefore be beneficial 
not only to the ~35% of ovarian cancers with high 
HER2 expression, but also in cases with medium to low 
HER2 expression. Although also effective in HER2-low 
expressing cancer, the PCI-induced efficacy of MH3-B1/
rGel clearly correlates with HER2 expression [23] (Fig. 
3). Off-target effects of the treatment in HER2 positive 
normal cells should, in addition, be of minor importance 
since off-target tissue in general (except in the liver) will 
accumulate less PS [42] and will not be subjected to light 
exposure. The present report warrants further evaluation 
in preclinical ovarian cancer models. These studies will 
also include pharmacologic evaluation to conclude on the 
mechanisms of cell death induced by the treatment. The in 
vivo protocol must, however, be optimized with respect to 
MH3-B1/rGel dose. 
MAterIAls And MetHods
cell lines and cultivation
Four HER2 overexpressing cell lines were used in 
this study. The ovarian adenocarcinoma cell line SKOV-
3 (ATCC, HTB-77™), purchased from American Type 
Culture Collection (ATCC, Manassas, VA, USA), the 
human breast adenocarcinoma cell line SK-BR-3, kindly 
provided by the Department of Biochemistry, Institute 
for Cancer Research, Norwegian Radium Hospital, Oslo 
University Hospital, Oslo, Norway, the human ovarian 
carcinoma cell line HOC-7, kindly provided by Dr. 
Yvonne Anderson, Department of Tumor Biology, Institute 
for Cancer Research, Norwegian Radium Hospital, Oslo 
University Hospital, Oslo, Norway, and the rat ovarian 
cancer cell line NuTu-19, originally a gift from Dr. A.L 
Major, University of Geneva, Switzerland [22]. The 
HER2 low expressing human breast adenocarcinoma cell 
line MDA-MB-468 (ATCC, HTB-132TM) was obtained 
from ATCC. SKOV-3 and SK-BR-3 cells were cultured 
in McCoy’s 5A medium while HOC-7 and NuTu-19 
cells were cultured in RPMI 1640 medium. Both media 
were obtained from Sigma-Aldrich (St. Louis MO) and 
modified as previously described [23]. The MDA-MB-468 
cells were cultured in Leibovitz`s L-15 medium (Lonza, 
Basel, Switzerland) modified as previously described [23] 
with free gas exchange with atmospheric air. 
Preparation of MH3-b1 and MH3-b1/rGel 
The HER2-targeted single chain antibody-fragment 
MH3-B1 and the HER2-targeted recombinant fusion toxin 
MH3-B1/rGel were produced as previously reported [9]. 
rGel is the recombinant version of the type I RIP gelonin.
evaluation of cytotoxicity
The MTT viability assay was in the present study 
used to assess cytotoxicity of the different treatments. 
Cytotoxicity data, as measured by clonal cell survival, has 
previously been compared with MTT data as obtained here 
[24, 25]. No significant difference has been observed in 
these studies. 
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evaluation of Her2-targeted therapeutics 
Cells were seeded at 2.5x103 (SKOV-3), 6.0x103 
(SK-BR-3), 2x103 (HOC-7) and 1.5x103 (NuTu-19) cells/
well in 96-well plates (Nunc) and allowed to attach to 
the substratum overnight. The cells were then subjected 
to a 72 hrs incubation of increasing concentrations of 
trastuzumab (Hoffmann-La Roche, Basel, Switzerland) 
or the scFv MH3-B1. To examine the cytotoxicity of the 
immunotoxin MH3-B1/rGel, the cells were incubated 
with MH3-B1/rGel or rGel for 4 or 72 hrs and the MTT 
viability assay was done 72 hrs post treatment initiation 
for both incubation procedures as previously reported [23]. 
IC50 (72 hrs incubation) or IC35 (4 hrs incubation) values 
of MH3-B1/rGel and rGel were calculated from sigmoidal 
curves (see 2.11) and used for establishing the targeting 
index (TI) of MH3-B1/rGel:
*Formula for calculating the TI at IC50 (TI50) for 
rGel and MH3-B1/rGel. The TI at IC35 (TI35) was assessed 
by the same formula inserting the IC35 values.
light source 
The cells were exposed to light from LumiSource® 
(PCI Biotech AS, Oslo, Norway), delivering blue light 
(λmax = 435 nm) from a bank of four 18W Osram L 18/67 
light tubes with an irradiance of 12.6 mW/cm2, varying 
less than 10 % across the illumination area.
PcI of MH3-b1/rGel in vitro
The PS TPCS2a (meso-tetraphenyl chlorin with two 
sulfonate groups on adjacent phenyl rings, Amphinex®) 
was provided by PCI Biotech AS. Experiments with 
TPCS2a were performed under subdued light. Cells were 
seeded at 10x103 (SK-BR-3), 5x103 (SKOV-3), 3x103 
(HOC-7) and 2x103 (NuTu-19) cells/well in 96-well plates 
(Nunc) and allowed to attach for 6 hrs. MDA-MB-468 
were seeded at 8x103 cells/well and attached over night. 
Cells were then subjected to 0.4 µg/ml (SK-BR-3, SKOV-
3, HOC-7 and NuTu-19) or 0.1 µg/ml (MDA-MB-468) 
TPCS2a for 18 hrs, washed twice with culture medium and 
incubated with 2 nM MH3-B1/rGel for 4 hrs before the 
medium was replaced with new drug-free culture medium 
and the cells exposed to increasing doses of light from 
LumiSource®. All treatment regimens were performed in 
triplicates and the MTT assay was used for cell viability 
evaluation 48 hrs (SK-BR-3, HOC-7, NuTu-19 and MDA-
MB-468) or 96 hrs (SKOV-3) after light exposure as 
previously reported [23]. PCI efficacy was corrected for 
cellular sensitivity to rGel treatment as follows [23]:
 where PCI efficacy is described as:
where the photochemical treatment is the 
combination of PS and light without any protein toxin 
added and  IC50 rGel refers to the rGel concentration in 
nM.
Thus,
Western blot analysis
For assessment of HER2 expression, sample 
preparation and western blotting were performed as 
previously described [23]. Three different substrate 
detection systems were used on the Western blots 
dependent on the band signal; LumiGlo chemiluminescent 
substrate system (KPL, Gaithesburg, MD USA), 
Supersignal West Dura Extended duration Substrate 
(Thermo Scientific, Rockford, IL, USA) and Supersignal 
West Femto Maximum Sensitivity Substrate (Thermo 
Scientific). Unfortunately, we were not able to find any 
antibody recognizing rat HER2.
For detection of HER2 and MH3-B1/rGel in SKOV-
3 tumors, MH3-B1/rGel was injected i.v. at 2 mg/kg when 
the tumors reached 200mm3. The tumors were harvested 
48 hrs post injection and prepared as previously described 
[26]. Prior to SDS-PAGE, the samples were mixed with 
5x reducing buffer and western blotting was performed 
as recently described [23]. The primary anti-gelonin 
polyclonal antibody was established by the Rosenblum 
lab. 
cellular uptake and localization of Alexa488-
MH3-b1/rGel
Alexa488-labeled MH3-B1/rGel was prepared as 
recently described [23]. For evaluation of cellular uptake 
of Alexa488-MH3-B1/rGel, cells were seeded at 4x105 
(SK-BR-3) and 3x105 (SKOV-3) cells/well in 6-well 
plates and treated and analyzed as previously reported by 
a BD FACSCalibur™ flow cytometer and BD CellQuest™ 
software (Becton-Dickinson) [23]. 
Alexa488-MH3-B1/rGel was also used to evaluate 
the cellular localization of MH3-B1/rGel by confocal 
microscopy in the presence of Lysotracker® (LTR) as 
recently reported [23]. 
To calculate the degree of overlap between the 
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chromophores Alexa488-MH3-B1/rGel and LTR, the 
weighted colocalization coefficient Manders’ thresholded 
coefficient (MTC) was used. The calculation of the MTC 
designates the sum of intensities of colocalizing pixels in 
the respective channel, as compared to the overall sum of 
pixel intensities above threshold and formulated by:
where Ch1i,coloc is the fluorescence intensity of 
Alexa488-MH3-B1/rGel in each pixel where the intensity 
of LTR is above threshold, and ΣCh1i is the sum of 
Alexa488-MH3-B1/rGel pixel intensities above threshold 
in the cells. A threshold was set above the noise level 
for each chromophore, and was determined by imaging 
control cells in the absence of LTR and PS. The same 
threshold was used in all cells [27]. 
The Pearson’s correlation coefficient (PCC) was 
used to calculate the correlation between the fluorescence 
intensity of Alexa488-MH3-B1/rGel and LTR where 
a value of 1 represents 100 % positive correlation, 0 
indicates no correlation and -1 represents a total negative 
correlation formulated by:
where Ch1i and Ch2i is the fluorescence intensity 
from Alexa488-MH3-B1/rGel and LTR in each pixel, 
respectively, and Ch1avg and Ch2avg are the average 
intensity values of the two chromophores [27]. All 
calculations were made from nine measured cells from 
three independent experiments. 
PcI of MH3-b1/rGel in vivo
All handling of animals were performed according 
to standards set by the institutional animal care and use 
committee, in compliance with the Norwegian Animal 
Research Authority’s guidelines. Cultured subconfluent 
SKOV-3 cells were injected subcutaneously on the left 
leg of Hsd:Athymic Nude-Foxn1nu female mice (5x106 
cells/animal). At a tumor size of 75-225 mm3, the mice 
were randomly assigned to 4 treatment groups; no 
treatment, MH3-B1/rGel, photochemical treatment and 
PCI of MH3-B1/rGel. The PS TPCS2a was administered 
intravenously at 5 mg/kg 72 hrs prior to light exposure 
and 2 mg/kg (100 µl of 0.534 mg/ml stock solution) of 
MH3-B1/rGel was injected intravenously 24 hrs or 48 hrs 
before light exposure. Tumors were illuminated by a 652 
nm diode laser (CeramOptec GmbH, Bonn, Germany) 
equipped with a laserfiber (Medlight SA, Ecublens, 
Switzerland) at an irradiance of 90 mW cm-2 and a total 
dose of 20 J cm-2. Sevoflurane inhalation gas was used as 
an anesthetic during light exposure and body temperature 
was maintained by placing the animal on a water-heated 
plate. The mice were covered by aluminum foil during 
light exposure, exposing only the tumor area and a ~2 mm 
margin to light. Tumor volume, measured by a caliper, and 
weight were monitored 2-3 times a week. Tumor volume 
was calculated by the equation; 0.5 x L x W2 (L = length 
and W = width of tumor). Animals were euthanized by 
cervical dislocation when tumor volume exceeded 1000 
mm3. 
Assessment of liver and kidney toxicity
The animals were divided in 2 groups: no-treatment 
and PCI of MH3-B1/rGel with 4 animals in each 
group. The animals were anesthetized and subjected to 
cardiac puncture 24 hrs after light exposure when 1 ml 
whole blood was transferred with a 1 ml syringe (27 
G Kidneys) to a 4 ml LH Lithium Heparin Separator 
(Greiner Bio One, Austria). The tubes were subjected to 
a 15 min centrifugation at 2500 G and serum aspartate 
aminotransferase (AST), alanine aminotransferase (ALT) 
and creatinine were assayed on a Cobas6000 (Roche 
Diagnostics, Mannheim, Germany) within 1.5 hrs after 
blood sampling. and liver were removed immediately 
after cardiac puncture and fixed 3 days in formalin prior 
to H&E staining as previously described [21]. One of the 
PCI of MH3-B1/rGel treated animals was excluded from 
the study due to difficulties with the cardiac puncture. 
statistical analysis
Sigmaplot™ version 12.5 (Systat Software Inc., 
San Jose, CA, USA) and IBM SPSS (IBM Corporation, 
Armonk, New York, US) were used for statistical analysis. 
A 2-sided Student’s t-test was used to measure statistical 
differences and a value of p < 0.05 was considered 
statistically significant.
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